<div class="KonaFilter image-container display-table full"><div><div class="image on-image"></div></div></div>The 2015 Stanley Cup Finals between the Chicago Blackhawks and Tampa Bay Lightning is a matchup of two star-studded teams. The Blackhawks, the <a href="http://www.vegasinsider.com/nhl/odds/futures/">slight favorites</a>, will rely on veterans as they try to win their third Stanley Cup in six years. The Lightning, who haven't won a Stanley Cup since 2004, will be powered by a bunch of players who are just making names for themselves in the NHL.Here's what you need to know about both teams:<h2>Chicago Blackhawks</h2>The Blackhawks are a finesse team. Their ability to move the puck up ice in a hurry with crisp passes will put pressure on the Tampa defense. The depth of Chicago is notable as all four lines can score.Up front, the Blackhawks are led by Jonathan Toews (9 goals, 9 assists, 18 points) and Patrick Kane (10 goals, 20 points). The toughness of Toews exemplifies this Blackhawks team, which has four overtime wins (two in double OT, two triple OT) in the 2015 postseason. Kane is one of the most exciting players in the league. "His skill with the puck is probably the best in the league," <a href="https://twitter.com/ChrisKuc/status/605772915292782592">Tampa Bay defenseman Victor Hedman told the Chicago Tribune</a>. Throw in veterans Brad Richards, Patrick Sharp and Marian Hossa, young stud Brandon Saad, and the scrappy Andrew Shaw, and the Blackhawks have depth that make them tough to beat.<div class="KonaFilter image-container display-table"><div><div class="image on-image"></div></div></div>At defense, the Blackhawks rely heavily on their top four. Duncan Keith (2 goals, 18 points) averages 31:35 of ice time per contest to lead all skaters, and is considered one of the front-runners for the Conn Smthye trophy, given to the most valuable player throughout the playoffs. Add Brent Seabrook, Niklas Hjalmarsson and Johnny Oduya, and the Blackhawks have one of the stronger top 4 pairings in the league.In goal for the Blackhawks is Corey Crawford. After being replaced for a lackluster Game 1 performance in the first round of the playoffs, Crawford has come on strong to amass a 9-4 record with a 2.56 goals against average and 91.9% save percentage.<h2>Tampa Bay Lightning</h2>Tampa Bay has offensive firepower of its own. The speed of Tampa's youngsters will put pressure on the Blackhawks, and could wear out the heavily relied upon top-four Chicago defensemen. The Lightning's power play will be crucial, having scored at least one goal with a man advantage in five of seven games against the Rangers in the Eastern Conference Finals. Tyler Johnson is the man to watch. At 24 years old he leads the playoffs in scoring with 12 goals and 21 points in just his second full season. Johnson is supported by fellow 24-year old Ondrej Palat (7 goals 15 points), 25 year olds Steven Stamkos (7 goals, 17 points) and Alex Killorn (7 goals, 16 points) and 21-year old Nikita Kucherov. The Lightning look up to the veteran leadership of Brian Boyle and Anton Stralman who were added in the offseason, joining former New York Rangers teammate Ryan Callahan, who was acquired at the 2014 trade deadline.<div class="KonaFilter image-container display-table"><div><div class="image on-image"></div></div></div> The Lightning have depth along the blue line. They routinely dress seven defensemen instead of the usual six. Hedman and Stralman anchor the Tampa Bay defense and at 23:24 and 22:13 per game, trail all of Chicago's top 4. Killorn, Jason Garrison, Matthew Carle, Braydon Coubron and Andrej Sustr all log more than 16 minutes per contents.As impressive as Corey Crawford has looked, Tampa Bay's Ben Bishop has been better. While Bishop's record (12-8) isn't as impressive, he a sparkling 2.15 goals against average while saving 92.0% of the shots he has faced.<h2>Stanley Cup Finals Schedule</h2>Game 1: Wednesday, June 3, at Tampa, 8 p.m. ET, NBCGame 2: Saturday, June 6, at Tampa, 7:15 p.m. ET, NBCGame 3: Monday, June 8, at Chicago, 8 p.m. ET, NBC Sports Game 4: Wednesday, June 10, at Chicago, 8 p.m. ET, NBC Sports Game 5 (if necessary): Saturday, June 13, at Tampa, 8 p.m. ET, NBCGame 6 (if necessary): Monday, June 15, at Chicago, 8 p.m. ET, NBCGame 7 (if necessary): Wednesday, June 17, at Tampa, 8 p.m. ET, NBC <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/how-floyd-mayweather-spends-his-money-boxing-2015-4">Here's how Floyd Mayweather spends his millions</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="NiaGVpdDqdBR4NCmtjL5odLe14N1R4Hp" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

Everything you need to know about the Stanley Cup Finals

FA Insights is a daily newsletter from Business Insider that delivers the top news and commentary for financial advisors.
<a href="http://www.agaryshilling.com/index.html">Gary Shilling Has Eight Investment Themes For The Grand Disconnect</a> (A. Gary Shilling's Insight)
In a new note, Gary Shilling highlights eight investment themes for the Grand Disconnect. "This Grand Disconnect between robust security markets and subdued at best economic reality, combined with central bank-set low interest rates, has spawned many distortions and a zeal for yield that almost completely ignores financial risks,"
These themes include 1. Treasury bonds 2. "Investment-grade bonds and dividend-rich stocks." 3. Small luxury stocks. 4. Consumer staples and food stocks. 5. Selected health care stocks and owning medical office buildings. 6. Productivity enhancers like tech companies. 7. The dollar against the yen, and Japanese stocks. 8. "North American energy producers ex-renewables."
Shilling has dropped direct ownership of rental apartments from the list. He has also thinks commodities are bad investments. 
<a href="http://online.wsj.com/article/SB10001424127887323550604578410931070034520.html">Four Broker Teams Join Morgan Stanley's Wealth Management Unit</a> (The Wall Street Journal)
Four teams of brokers that manage a combined $765 million in assets have joined Morgan Stanley's wealth management unit. These broker teams include Gaston Abello and Felix Jaimovich moved from Bank of America. Paul D. Emrick, Troy Hottenstein and Scott Holland left JP Morgan for Morgan Stanley. William Seabrook and Kathleen Chiappone joined from Wells Fargo. And Robert Iocco and Francis Ciocari left Merrill Lynch Wealth Management.
Morgan Stanley has lost about 70 veteran advisors since the start of the year. 
<a href="http://www.businessinsider.com/chart-corporate-cash-use-since-1998-2013-4">Companies Are Using More Of Their Cash For Dividends And Stock Buybacks</a> (Goldman Sachs)
Corporations have typically used their cash balance for share buybacks, dividends, acquisitions, research and development and capital expenditures. But recently, they have been sending more cash back to shareholders.
<div class="image-container click-to-enlarge" style="width:590px"><div class="image"><a title_source="Goldman Sachs" title_caption="" class="zoomin" href="http://static5.businessinsider.com/image/5163052deab8ea497b000002-960/moneygame-cotd-040813.jpg"></a></div>Goldman Sachs</div>
 
<a href="http://www.businessinsider.com/march-madness-is-over-prepare-for-april-anxiety-2013-4">Investors Should Prepare For 'April Anxiety'</a> (S&amp;P Capital IQ) 
With stocks ending on a record high in the first quarter, S&amp;P Capital IQ's Sam Stovall thinks investors are lulling themselves into complacency. 
"History has shown that actual earnings frequently outpace expectations. What’s more, analysts are optimistic about forward guidance, based on the expected improvement in the global economic growth trajectory.
"However, an elevated negative-to-positive guidance ratio and a variety of headwinds could cause Q1 2013 results to replace Q2 2012 EPS as the trough quarter for this earnings cycle. As a result, the uncertainty over Q1 2013 EPS growth and forward guidance will probably allow for a seamless transition of tension from March Madness to April Anxiety."
<a href="http://newsandinsight.thomsonreuters.com/Legal/News/2013/04_-_April/SEC_settles_with_woman_whose_brother_sent_her_tips_to_SAC_manager/">SEC Settles With Woman Who Tipped Her Brother, Who In Turn Tipped Off SAC Manager</a> (Thomson Reuters News &amp; Insight)<a href="http://newsandinsight.thomsonreuters.com/Legal/News/2013/04_-_April/SEC_settles_with_woman_whose_brother_sent_her_tips_to_SAC_manager/"></a>
The SEC has settled its lawsuit against ThanhHa Bao. Bao was charged with illegally tipping of her brother on earnings of medical devices company Abaxis Inc.
Her brother was accused of passing the information on to a former SAC Capital Advisors fund manager Noah Freeman, and Samir Barai, founder of Barai Capital Management.
The brother was sentenced to 366 days in prison and a fine of $400,000. Bao has agreed to pay $144,910 to settle her charges.

5 Smart Insights For Financial Advisors

The new antibiotic was discovered in a sample of soil.
The research is "ingenious," Dr. William Schaffner, an infectious disease specialist at Vanderbilt University, <a href="http://www.nytimes.com/2015/01/08/health/from-a-pile-of-dirt-hope-for-a-powerful-new-antibiotic.html">told The New York Times</a>.
Researchers said the antibiotic, which has yet to be tested in humans, could one day be used to treat drug-resistant infections caused by the superbug MRSA, as well as tuberculosis, which normally requires a combination of drugs that can have adverse side effects.
Antibiotic-resistant infections <a href="http://www.businessinsider.com/superbugs-will-kill-10-million-a-year-by-2050-2015-1">already kill 700,000 people each year</a>, with those numbers expected to rise.
"The discovery of this novel compound challenges long-held scientific beliefs and holds great promise for treating an array of menacing infections," said Kim Lewis, a professor at Northeastern University and co-founder of the NovoBiotic Pharmaceuticals, which has patented teixobactin.
Still, experts urged caution. Though the researchers said they didn't see signs of poisoning in the mice treated with teixobactin, antibiotics that show promise in mice are often toxic to humans. 
"It's at the test-tube and the mouse level, and mice are not men or women," Schaffner <a href="http://www.nytimes.com/2015/01/08/health/from-a-pile-of-dirt-hope-for-a-powerful-new-antibiotic.html">told The Times</a>. "Moving beyond that is a large step, and many compounds have failed." 
<h3>A New Kind Of Antibiotic</h3>
Lewis worked with researchers at Germany's University of Bonn and with Britain's Selcia Limited, and the finding was published in the journal <a href="http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14098.html">Nature</a> on Wednesday.
His co-researcher, Bonn's Tanya Schneider, explained in a teleconference that teixobactin belongs to a new class of compounds and kills bacteria by causing their cell walls to break down. It seems to work by binding to multiple targets, she said, which may slow down the development of resistance. (Lewis estimated that it would take target bacteria 30 years or more to develop resistance to teixobactin, though that timeframe likely depends on how widely the drug is prescribed if it ends up on the market.)
The problem of infections developing drug resistance - a feature of medicine since Alexander Fleming's discovery of the first antibiotic, penicillin, in 1928 - has worsened in recent years as multi-drug-resistant bugs have developed and drug companies have cut investment.
The World Health Organization warned last year that a post-antibiotic era, where even basic healthcare becomes dangerous due to risk of infection during routine operations, could come this century unless something drastic is done.
<h3>More Where This Came From?</h3>
Lewis and his NovoBiotic colleagues sought to address the problem by tapping into new potential sources of antibiotics.
"The new research is based on the premise that everything on earth - plants, soil, people, animals - is teeming with microbes that compete fiercely to survive," Denise Grady <a href="http://www.nytimes.com/2015/01/08/health/from-a-pile-of-dirt-hope-for-a-powerful-new-antibiotic.html">explained in The Times</a>. "Trying to keep one another in check, the microbes secrete biological weapons: antibiotics."
The team behind the new discovery developed a way of growing such microbes in their natural environment using a miniature device called an iChip that can isolate and help grow single cells.
Researchers have had trouble growing most bacteria outside of their natural environment, which makes it hard to study potential new antibiotics. The iChip, which bring the natural environment into the lab, may end up being a more important innovation than teixobactin itself.
"The method has the potential to be truly transformative, giving us access to a much greater diversity of environmental bacteria than previously imagined," Gautam Dantas, a Washington University scientist who specializes in antibiotic resistance, <a href="http://phenomena.nationalgeographic.com/2015/01/07/antibiotic-resistance-teixobactin/">told science writer Ed Yong</a>.
The development of the iChip method means that Lewis and his team are well-positioned to discover even more good candidates for future antibiotics. "Teixobactin is a fish; the iChip is the rod," <a href="http://phenomena.nationalgeographic.com/2015/01/07/antibiotic-resistance-teixobactin/">Yong explained</a>. "Having the rod guarantees that we'll get more fish - and we desperately need more."
NovoBiotic has so far collected about 50,000 strains of uncultured bacteria and discovered 25 new antibiotics, of which teixobactin is the latest and most interesting, Lewis said. "The rule of thumb in antibiotic discovery is if you have 50 good leads, from those you will get one drug," Lewis explained. "That's just the reality."
One recent discovery, for example, proved to be too toxic to be used as an antibiotic, and is now being tested as a potential anticancer agent.
<h3>Proceed With Caution</h3>
Scientists not involved in the work welcomed the finding, but cautioned that human trials of teixobactin would be key.
"The discovery of a potential new class of antibiotics is good news," said Richard Seabrook of Britain's Wellcome Trust medical charity. "Screening previously unculturable soil bacteria is a new twist in the search ... and it is encouraging to see this approach yielding results. However, we will not know whether teixobactin will be effective in humans until this research is taken ... to clinical trials."
Lewis hopes to begin those trials in about two years, and noted that even though the research has not been especially costly so far, they will need significant funding to bring the drug to market.
Even if all goes perfectly - and researchers could still discover problems that halt development - teixobactin won't be available in hospitals for at least five years. It will be more expensive than generic antibiotics, and would likely take the form of an injection, not a pill. 
(<a href="http://www.reuters.com/article/2015/01/08/us-health-antibiotic-discovery-idUSKBN0KH10S20150108">Reuters</a> reporting by Kate Kelland; Editing by Ruth Pitchford)

Ingenious' Antibiotic Discovery 'Challenges Long-Held Scientific Beliefs

Scientists have discovered a new antibiotic, teixobactin, that can kill serious infections in mice without encountering any detectable resistance, offering a potential new way to get ahead of dangerous evolving superbugs.&#xa0;
The new antibiotic was discovered in a sample of soil.
The research is "ingenious," Dr. William Schaffner, an infectious disease specialist at Vanderbilt University, <a href="http://www.nytimes.com/2015/01/08/health/from-a-pile-of-dirt-hope-for-a-powerful-new-antibiotic.html">told The New York Times</a>.
Researchers said the antibiotic, which has yet to be tested in humans, could one day be used to treat drug-resistant infections caused by the superbug MSRA, as well as tuberculosis, which normally requires a combination of drugs that can have adverse side effects.
Antibiotic-resistant infections <a href="http://www.businessinsider.com/superbugs-will-kill-10-million-a-year-by-2050-2015-1">already kill 700,000 people each year</a>, with those numbers expected to rise.
"The discovery of this novel compound challenges long-held scientific beliefs and holds great promise for treating an array of menacing infections," said Kim Lewis, a professor at Northeastern University and co-founder of the NovoBiotic Pharmaceuticals, which has patented teixobactin.
Still, experts urged caution. Though the researchers said they didn't see signs of poisoning in the mice treated with teixobactin, antibiotics that show promise in mice are often toxic to humans.&#xa0;
"It's at the test-tube and the mouse level, and mice are not men or women,"&#xa0;Schaffner <a href="http://www.nytimes.com/2015/01/08/health/from-a-pile-of-dirt-hope-for-a-powerful-new-antibiotic.html">told The Times</a>.&#xa0;"Moving beyond that is a large step, and many compounds have failed."&#xa0;
<h3>A New Kind Of Antibiotic</h3>
Lewis worked with researchers at Germany's University of Bonn and with Britain's Selcia Limited, and the finding was published in the journal&#xa0;<a href="http://www.nature.com/nature/journal/vaop/ncurrent/full/nature14098.html">Nature</a>&#xa0;on Wednesday.
His co-researcher, Bonn's Tanya Schneider, explained in a teleconference that teixobactin belongs to a new class of compounds and kills bacteria by causing their cell walls to break down. It seems to work by binding to multiple targets, she said, which may slow down the development of resistance. (Lewis estimated that it would take target bacteria 30 years or more to develop resistance to teixobactin, though that timeframe likely depends on how widely the drug is prescribed if it ends up on the market.)
The problem of infections developing drug resistance - a feature of medicine since Alexander Fleming's discovery of the first antibiotic, penicillin, in 1928 - has worsened in recent years as multi-drug-resistant bugs have developed and drug companies have cut investment.
The World Health Organization warned last year that a post-antibiotic era, where even basic healthcare becomes dangerous due to risk of infection during routine operations, could come this century unless something drastic is done.
<h3>More Where This Came From?</h3>
Lewis and his NovoBiotic colleagues sought to address the problem by tapping into new potential sources of antibiotics.
"The new research is based on the premise that everything on earth - plants, soil, people, animals - is teeming with microbes that compete fiercely to survive," Denise Grady <a href="http://www.nytimes.com/2015/01/08/health/from-a-pile-of-dirt-hope-for-a-powerful-new-antibiotic.html">explained in The Times</a>. "Trying to keep one another in check, the microbes secrete biological weapons: antibiotics."
The team behind the new discovery developed a way of growing such microbes in their natural environment using a miniature device called an iChip that can isolate and help grow single cells.
Researchers have had trouble growing most bacteria outside of their natural environment, which makes it hard to study potential new antibiotics. The iChip, which bring the natural environment into the lab, may end up being a more important innovation than teixobactin itself.
"The method has the potential to be truly transformative, giving us access to a much greater diversity of environmental bacteria than previously imagined,"&#xa0;Gautam Dantas, a Washington University&#xa0;scientist who specializes in antibiotic resistance,&#xa0;<a href="http://phenomena.nationalgeographic.com/2015/01/07/antibiotic-resistance-teixobactin/">told science writer Ed Yong</a>.
The development of the iChip method means that Lewis and his team are well-positioned to discover even more good candidates for future antibiotics. "Teixobactin is a fish; the iChip is the rod," <a href="http://phenomena.nationalgeographic.com/2015/01/07/antibiotic-resistance-teixobactin/">Yong explained</a>. "Having the rod guarantees that we'll get more fish - and we desperately need more."
NovoBiotic has so far collected about 50,000 strains of uncultured bacteria and discovered 25 new antibiotics, of which teixobactin is the latest and most interesting, Lewis said. "The rule of thumb in antibiotic discovery is if you have 50 good leads, from those you will get one drug," Lewis explained. "That's just the reality."
One recent discovery, for example, proved to be too toxic to be used as an antibiotic, and is now being tested as a potential anticancer agent.
<h3>Proceed With Caution</h3>
Scientists not involved in the work welcomed the finding, but cautioned that human trials of teixobactin would be key.
"The discovery of a potential new class of antibiotics is good news," said Richard Seabrook of Britain's Wellcome Trust medical charity. "Screening previously unculturable soil bacteria is a new twist in the search ... and it is encouraging to see this approach yielding results. However, we will not know whether teixobactin will be effective in humans until this research is taken ... to clinical trials."
Lewis hopes to begin those trials in about two years, and noted that even though the research has not been especially costly so far, they will need significant funding to bring the drug to market.
Even if all goes perfectly - and researchers could still discover problems that halt development - teixobactin won't be available in hospitals for at least five years. It will be more expensive than generic antibiotics, and would likely take the form of an injection, not a pill.&#xa0;(Reuters by Kate Kelland; Editing by Ruth Pitchford)

You Searched For "seabrook" and got 7 results

Everything you need to know about the Stanley Cup Finals

Jonathan Garber

5 Smart Insights For Financial Advisors

Mamta Badkar

Ingenious' Antibiotic Discovery 'Challenges Long-Held Scientific Beliefs

Lauren F Friedman,Reuters

Ingenious' Antibiotic Discovery 'Challenges Long-Held Scientific Beliefs

Lauren F Friedman,Reuters

These 1,429 US Towns Could Be Destroyed By Rising Sea Levels

Jennifer Welsh

Planned Parenthood's president on standing up for what you believe in

Richard Feloni,Dan Bobkoff,No…

Planned Parenthood's Cecile Richards on stepping down this year, battling Congress, and why she's a 'troublemaker' who's never looking for a fight

Richard Feloni,Daniel Richards